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Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), 
BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of treatment of small coronary artery disease with diabetes 
mellitus (DM).
Methods: A prospective analysis of 1670 patients with diabetic small coronary artery stenosis (420 SES, 360 PES, 249 ZES, 200 BES, 153 ECS, 
288 EES) in six high volume Asian centers after successful stent implantation was performed. The study endpoints were major adverse events (MACE) 
at 30 days, 12 months restenosis rate and target lesion revascularization (TLR) at 12 months. 
Results: See table for clinical Results. 
Conclusion: The use of drug-eluting stents in patients with diabetic small coronary artery stenosis was safe and feasible. Patients treated with BES 
and EES showed lesser rate of restenosis compared with ECS. 
SES PES ZES-R BES ECS EES
Number of patients 420 360 249 200 153 288
Multivessel disease (%) 75.2 72.5 76.3 75.0 75.8 77.8
MACE at 30 days (%) 1.0 0.8 0.3 1.0 0.7 0.3
Lesion length (mean: mm) 25.8 23.9 28.6* 28.0 25.6 29.8*
Lesion type: % of B2, C (%) 54.8 55.3 53.8 57.0 57.5 57.6
Reference diameter (mean: mm) 2.44 2.43 2.47 2.48 2.45 2.43
Lesion length (mean: mm) 19.6 18.3 21.7 20.8 22.9 22.0
MLD post procedure (mean: mm) 2.32 2.28 2.39 2.35 2.33 2.31
12 months MLD (mean: mm) 2.13 2.04 2.21 2.18 1.73 2.12
Restenosis rate (%) 13.3 17.2 12.9 8.0** 32.7 9.4**
TLR (%) 10.7 15.0 10.4 7.0** 26.1 6.9**
MACE (%) 11.6 17.2 11.2 8.0** 28.1 8.0**
MLD: minimum lumen diameter, * p<0.05 vs. PES, **p<0.05 vs. ECS and PES.
